Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
August 21 2024 - 1:15AM
Allschwil, Switzerland, August 21, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a
commercial-stage biopharmaceutical company committed to meeting the
needs of patients with severe bacterial and fungal infections,
announced today that the continued strong sales performance of the
antifungal Cresemba® (isavuconazole) by its license partner Pfizer
Inc. in the Asia Pacific region and China exceeded the sales
threshold triggering a USD 1.25 million milestone payment.
David Veitch, Basilea’s Chief Executive Officer, stated:
“Achieving the threshold for the third milestone payment for Asia
Pacific and China this year, underscores the strong sales
performance and growth of Cresemba in this region. We are pleased
that Cresemba continues to meet the medical needs of patients
suffering from life-threatening invasive mold infections.”
The license agreement between Basilea and Pfizer for Cresemba
covers Europe (excluding the Nordic countries) as well as 16
countries in the Asia Pacific region and China.
Cresemba is approved and marketed in more than 70 countries,
including the United States, most EU member states and additional
countries inside and outside of Europe. According to the latest
available market data, total global in-market sales of Cresemba
amounted to USD 489 million in the 12 months between
April 2023 and March 2024, a 24 percent growth year-on-year.1
About isavuconazole
(Cresemba®)
Isavuconazole is an intravenous (i.v.) and oral azole
antifungal, commercialized under the trade name Cresemba®. Basilea
has entered into several license and distribution agreements for
isavuconazole covering approximately 115 countries. In the
27 European Union member states, as well as in Iceland,
Liechtenstein, Norway and the U.K., isavuconazole is approved for
the treatment of adult patients with invasive aspergillosis and for
adult patients with mucormycosis for whom amphotericin B is
inappropriate.2 In China, the oral and intravenous formulations are
approved for the treatment of adult patients with invasive
aspergillosis and invasive mucormycosis. Isavuconazole is also
approved in the United States and several additional countries in
Europe and beyond, including Japan.3 It has orphan drug designation
in the US, Europe and Australia for its approved indications.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded
in 2000 and headquartered in Switzerland. We are committed to
discovering, developing and commercializing innovative drugs to
meet the needs of patients with severe bacterial or fungal
infections. We have successfully launched two hospital brands,
Cresemba for the treatment of invasive fungal infections and
Zevtera for the treatment of bacterial infections. In addition, we
have preclinical and clinical anti-infective assets in our
portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements, such as "believe", "assume", "expect",
"forecast", "project", "may", "could", "might", "will" or similar
expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its
business, including with respect to the progress, timing and
completion of research, development and clinical studies for
product candidates. Such statements involve certain known and
unknown risks, uncertainties and other factors, which could cause
the actual results, financial condition, performance or
achievements of Basilea Pharmaceutica Ltd, Allschwil to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Basilea Pharmaceutica Ltd, Allschwil is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD Head of Corporate
Communications & Investor RelationsBasilea Pharmaceutica
International Ltd, Allschwil Hegenheimermattweg 167b4123
AllschwilSwitzerland |
Phone |
+41 61 606 1102 |
E-mail |
media_relations@basilea.cominvestor_relations@basilea.com |
This press release can be downloaded from www.basilea.com.
References
- IQVIA Analytics Link, March 2024. In-market sales reported as
moving annual total (MAT) in US dollar.
- European Public Assessment Report (EPAR) Cresemba:
https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed:
August 20, 2024]
- The registration status and approved indications may vary from
country to country.